Therapeutic delivery最新文献

Naturally derived hydrogels for wound healing. 用于伤口愈合的天然水凝胶。

IF 3

Therapeutic delivery Pub Date : 2025-04-01 Epub Date: 2025-01-27 DOI: 10.1080/20415990.2025.2457928

Duy Toan Pham, Ngo Thi Ngoc Thuy, Nguyen Thi Phuong Thao, Le Thi Nhi, Bui Thi Phuong Thuy

{"title":"Naturally derived hydrogels for wound healing.","authors":"Duy Toan Pham, Ngo Thi Ngoc Thuy, Nguyen Thi Phuong Thao, Le Thi Nhi, Bui Thi Phuong Thuy","doi":"10.1080/20415990.2025.2457928","DOIUrl":"10.1080/20415990.2025.2457928","url":null,"abstract":"Natural hydrogels have garnered increasing attention due to their natural origins and beneficial roles in wound healing. Hydrogel water-retaining capacity and excellent biocompatibility create an ideal moist environment for wound healing, thereby enhancing cell proliferation and tissue regeneration. For this reason, naturally derived hydrogels formulated from biomaterials such as chitosan, alginate, gelatin, and fibroin are highly promising due to their biodegradability and low immunogenic responses. Recent integrated approaches to utilizing new technologies with bioactive agents have significantly improved the mechanical properties of hydrogels and the controlled release and delivery of active compounds, thereby increasing the efficiency of the treatment processes. Herein, this review highlights the advantages and the challenges of natural hydrogels in wound healing, focusing on their mechanical strength, controlled degradation rates, safety and efficiency validation, and the potential for incorporating advanced technologies such as tissue engineering and gene therapy for utilization in personalized medicine.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"349-363"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970767/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insight on the biomimetic of lysozyme interaction with functionalized iron oxide nanoparticles. 溶菌酶与功能化氧化铁纳米颗粒相互作用的仿生研究。

IF 3

Therapeutic delivery Pub Date : 2025-04-01 Epub Date: 2025-02-20 DOI: 10.1080/20415990.2025.2467029

Wael M Elshemey, Ahmed M Elgharib, Abdo A Elfiky, Mohamed M Fathy

{"title":"Insight on the biomimetic of lysozyme interaction with functionalized iron oxide nanoparticles.","authors":"Wael M Elshemey, Ahmed M Elgharib, Abdo A Elfiky, Mohamed M Fathy","doi":"10.1080/20415990.2025.2467029","DOIUrl":"10.1080/20415990.2025.2467029","url":null,"abstract":"Introduction: Lysozyme is a globular hydrolytic enzyme whose tissue level is imperative for various clinical diagnostics. High levels of lysozyme are related to several inflammatory disorders, that breakdown cartilaginous tissues. Recently nanostructures have become widely used as modulators for enzyme activity.Areas covered: This study delves into the influential role played by surface-modified iron oxide nanoparticles (IONPs) as novel lysozyme nano-inhibitors. Stern-Volmer plots results for lysozyme interaction with Cit-IONPs and Thy-IONPs reveal dynamic quenching constant (KSV) of 40.075 and 65.714 ml/mg, binding constant (Kb) of 1.539 × 103 and 4.418 × 103 ml/mg, and binding free energy (∆G°binding) of -43.563 KJ. mol-1 and -49.821 KJ. mol-1, respectively. Upon interaction with IONPs, the catalytic activity of lysozyme decreases due to conjugation with Thy-IONPs and Cit-IONPs compared to the free form of the enzyme. Computational approaches show that the citrate and thymoquinone molecules have binding affinities with lysozyme active residues of about -4.3 and -4.7 kcal/mol, respectively.Expert opinion/commentary: Both formulations of IONPs demonstrate high affinity toward lysozyme proteins. This work shows a higher binding affinity between lysozyme and Thy-IONPs than with Cit-IONPs. These findings suggest that Thy-IONPs represent a promising class of nano-inhibitors for lysozyme, opening new avenues for treating disorders associated with lysozyme overexpression.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"315-326"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Next-generation pharmaceuticals: the rise of sildenafil citrate ODF for the treatment of men with erectile dysfunction. 下一代药物：柠檬酸西地那非用于治疗男性勃起功能障碍的兴起。

IF 3

Therapeutic delivery Pub Date : 2025-04-01 Epub Date: 2025-01-12 DOI: 10.1080/20415990.2024.2445501

Emmanuele A Jannini, Shivani Ohri Vignesh, Tarek Hassan

{"title":"Next-generation pharmaceuticals: the rise of sildenafil citrate ODF for the treatment of men with erectile dysfunction.","authors":"Emmanuele A Jannini, Shivani Ohri Vignesh, Tarek Hassan","doi":"10.1080/20415990.2024.2445501","DOIUrl":"10.1080/20415990.2024.2445501","url":null,"abstract":"Orodispersible film (ODF) is one of the novel formulations that disintegrate rapidly in the mouth without the requisite for water compared to other conventional oral solid dosage formulations. This delivery system serves as a convenient mode of administration, especially in patients who have dysphagia and fluid restriction, being beneficial to pediatric, geriatric, and bedridden patients. A novel sildenafil ODF containing sildenafil citrate is formulated to be used in patients with erectile dysfunction (ED). This review discusses the advantages of ODF in improving compliance and satisfaction in these patients and describes the manufacturing techniques, evaluation tests, bioequivalence, and stability studies of sildenafil ODF. This formulation offers unique benefit to patients with ED by improving their acceptance and compliance and respecting their privacy and the need for a discreet treatment. Moreover, the comparison of pharmacokinetic parameters between the sildenafil ODF administered with and without water and the conventional film-coated tablet were similar. It also demonstrated reliable performance that yielded a consistent product, meeting all specifications at release and after three weeks of storage under stressed conditions (60°C). Sildenafil ODF warrants improved ease of intake, taste, portability, storage, and compliance among ED patients, making it the potential most preferred formulation and drug of choice.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"365-378"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142972245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Iron oxide nanoparticles: a versatile nanoplatform for the treatment and diagnosis of ovarian cancer. 氧化铁纳米颗粒：用于卵巢癌治疗和诊断的多功能纳米平台。

IF 3

Therapeutic delivery Pub Date : 2025-04-01 Epub Date: 2024-12-26 DOI: 10.1080/20415990.2024.2442301

Neelam Poonia, Vipan Kumar, Rudra Narayan Subudhi, Manoj Dalabehera, Anupama Setia, Kundan Singh Bora, Vimal Arora

{"title":"Iron oxide nanoparticles: a versatile nanoplatform for the treatment and diagnosis of ovarian cancer.","authors":"Neelam Poonia, Vipan Kumar, Rudra Narayan Subudhi, Manoj Dalabehera, Anupama Setia, Kundan Singh Bora, Vimal Arora","doi":"10.1080/20415990.2024.2442301","DOIUrl":"10.1080/20415990.2024.2442301","url":null,"abstract":"Ovarian cancer remains one of the main causes of human mortality, accounting for millions of deaths every year. Despite of several clinical options such as chemotherapy, photodynamic therapy (PDT), hormonal treatment, radiation therapy, and surgery to manage this disease, the mortality rate is still very high. This alarming statistic highlights the urgent need for innovative approaches to improve both diagnosis and treatment. Success stories of iron oxide nanoparticles, i.e. Ferucarbotran (Resovist®) and Ferrixan (Cliavist®) for liver imaging, CNS (Central nervous system) imaging, cell labeling, etc. have motivated researchers to explore these nanocarriers for treatment and diagnosis of different diseases. Iron oxide nanoparticles have improved the therapeutic efficacy of anticancer drugs through targeted delivery, heat/ROS (reactive oxygen species) generation on application of external energy and have also shown great potential as contrast agents for magnetic resonance imaging (MRI). Their unique magnetic properties enable sensitive imaging, and surface modification allows the attachment of specific biomolecules for targeted detection of ovarian cancer cells. Their unique properties, viz. magnetic responsiveness and surface functionalization, make them versatile tools for enhancing both imaging and therapeutic outcomes. Present article reviews the literature on the synthesis, functionalization, and applications of iron oxide nanoparticles in management of ovarian cancer.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"379-392"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in microneedles for enhanced functional angiogenesis and vascular drug delivery. 微针增强功能性血管生成和血管药物输送的最新进展。

IF 3

Therapeutic delivery Pub Date : 2025-04-01 Epub Date: 2025-02-25 DOI: 10.1080/20415990.2025.2468148

Ngoc Hong Nguyen, Thuy Trang Nguyen, Vu Khac Hoang Bui, Nhat Thang Thi Nguyen, Giau Van Vo

{"title":"Recent advances in microneedles for enhanced functional angiogenesis and vascular drug delivery.","authors":"Ngoc Hong Nguyen, Thuy Trang Nguyen, Vu Khac Hoang Bui, Nhat Thang Thi Nguyen, Giau Van Vo","doi":"10.1080/20415990.2025.2468148","DOIUrl":"10.1080/20415990.2025.2468148","url":null,"abstract":"Many therapeutic applications use the transdermal method to avoid the severe restrictions associated with oral medication delivery. Given the limitations of traditional drug delivery via skin, transdermal microneedle (MN) arrays have been reported to be versatile and very efficient devices due to their outstanding characteristics such as painless penetration, affordability, excellent medicinal efficacy, and relative safety. MNs have recently received increased attention for their ability to cure vascular illnesses such as hypertension and thrombosis, as well as promote wound healing via the angiogenesis impact. The integrant of method manufacturing and biodegradable material allows for the modification of MN form and drug release pattern, hence increasing the flexibility of such drug delivery. In this review, we focused on recent improvements in MN-mediated transdermal administration of protein and peptide medicines for improved functional angiogenesis and vascular therapy. We also provide an overview of the present applications of MNs-mediated transdermal protein and peptide administration, particularly in the realm of vascular system disease therapy. Finally, the current state of clinical translation and a forecast for future progress are provided.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"393-406"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative in-vitro and in-vivo evaluation of spherulites and cubosomes of Irinotecan for lung targeting. 伊立替康用于肺靶向的球粒和长方体体外和体内比较评价。

IF 3

Therapeutic delivery Pub Date : 2025-04-01 Epub Date: 2025-02-02 DOI: 10.1080/20415990.2025.2460421

Jatin Rawat, Ravikumar Kachhadiya, Hetal Thakkar

{"title":"Comparative in-vitro and in-vivo evaluation of spherulites and cubosomes of Irinotecan for lung targeting.","authors":"Jatin Rawat, Ravikumar Kachhadiya, Hetal Thakkar","doi":"10.1080/20415990.2025.2460421","DOIUrl":"10.1080/20415990.2025.2460421","url":null,"abstract":"Aims: The present investigation aimed at the comparative evaluation of the developed nanocarriers, viz. spherulites and cubosomes for lung targeting.Materials and methods: Both the spherulites and cubosomes were characterized for their entrapment efficiency, drug loading, size and zeta potential, in-vitro drug release profile, surface morphology, hemocompatibility, and in-vivo pharmacokinetic and lung biodistribution.Results and conclusions: The optimized batches of spherulites and cubosomes possessed high entrapment efficiency and drug loading with size around 200 nm, which is suitable for lung targeting. The zeta potential value for both the nanoformulations was found to be between -20 and -30 mv indicating the physical stability against aggregation. The SEM and TEM analysis revealed the presence of spherical and discrete particles in both the types of nanocarriers. Water channels were observed in case of cubosomes. Spherulites and cubosomes showed pH-dependent drug release with lower release at physiological pH while higher release at the pH of the tumor microenvironment. Both spherulites and cubosomes exhibited highly significant increase in the half-life and mean residence time in the plasma. The prepared nanoformulations were hemocompatible and had higher lung targeting potential compared to the plain drug solution.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"339-347"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Industry update: the latest developments in the field of therapeutic delivery, December 2024. 行业更新：2024年12月，治疗递送领域的最新发展。

IF 3

Therapeutic delivery Pub Date : 2025-04-01 Epub Date: 2025-03-06 DOI: 10.1080/20415990.2025.2472722

Peter Timmins

引用次数: 0

Nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels for site-specific buccal applications. 制霉菌素：β-环糊精和氯己定：β-环糊精黏附水凝胶用于特定部位的口腔应用。

IF 3

Therapeutic delivery Pub Date : 2025-04-01 Epub Date: 2025-02-20 DOI: 10.1080/20415990.2025.2467018

Amanda Aparecida Maia Neves Garcia, Juliana Aenishanslin, Carolina Yoshi Campos Sugio, Thais Letícia Moreira da Silva, Vanessa Migliorini Urban, Marina Tolentino Marinho, Benjamim de Melo Carvalho, Karin Hermana Neppelenbroek, Priscileila Colerato Ferrari

{"title":"Nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels for site-specific buccal applications.","authors":"Amanda Aparecida Maia Neves Garcia, Juliana Aenishanslin, Carolina Yoshi Campos Sugio, Thais Letícia Moreira da Silva, Vanessa Migliorini Urban, Marina Tolentino Marinho, Benjamim de Melo Carvalho, Karin Hermana Neppelenbroek, Priscileila Colerato Ferrari","doi":"10.1080/20415990.2025.2467018","DOIUrl":"10.1080/20415990.2025.2467018","url":null,"abstract":"Background: This study aimed to develop and analyze nystatin:β-cyclodextrin and chlorhexidine:β-cyclodextrin mucoadhesive hydrogels.Materials & methods: Hydrogels were characterized by in vitro and ex vivo analyses, and antifungal activity against Candida albicans.Results: The hydrogel showed high adhesiveness and retention (83.37 ± 2.05%) to the porcine oral mucosa. The drug release from complexed nystatin and chlorhexidine hydrogels was 1.5 (95 µg/cm2) and 4.0 times higher (800 µg/cm2) than non-complexed drugs. Rheological studies indicated the prevalence of elastic behavior of the formulations. Ex vivo permeation using porcine mucosa showed retention on the oral mucosa. Hydrogels with nystatin and chlorhexidine inclusion complex showed inhibition percentages of 88.87% and 91.57%, respectively, and median inhibition zones of 8 mm.Conclusion: Mucoadhesive hydrogels with inclusion complex are promising for oral lesions with greater retention at the treatment site.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"327-338"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic assessment and level-A IVIVC establishment of rifampicin-loaded 3D printed tablets using SLS 3D printing. SLS 3D打印载利福平3D打印片剂的药代动力学评价及a级IVIVC建立。

IF 3

Therapeutic delivery Pub Date : 2025-03-30 DOI: 10.1080/20415990.2025.2484169

Tukaram Karanwad, Dimple S Lalchandani, Sachin B Jorvekar, Santa Mandal, Pawan Kumar Porwal, Roshan M Borkar, Subham Banerjee

{"title":"Pharmacokinetic assessment and level-A IVIVC establishment of rifampicin-loaded 3D printed tablets using SLS 3D printing.","authors":"Tukaram Karanwad, Dimple S Lalchandani, Sachin B Jorvekar, Santa Mandal, Pawan Kumar Porwal, Roshan M Borkar, Subham Banerjee","doi":"10.1080/20415990.2025.2484169","DOIUrl":"https://doi.org/10.1080/20415990.2025.2484169","url":null,"abstract":"Background: This study investigated the in vitro dissolution and in vivo absorption of rifampicin (RIF)-containing 3D-printed tablets using Selective Laser Sintering (SLS) technology.Methods: In vitro dissolution was assessed in acidic (pH 1.2) and alkaline (pH 6.8) buffer media, while in vivo absorption was evaluated in a New Zealand White rabbit model. Both analytical and bioanalytical methods were rigorously developed and validated using LC-ESI-MS/MS, following ICH Q2 (R1) and FDA guidelines, respectively.Results: In the acidic medium, 16.22% of RIF was released within the first 2 h, whereas in the alkaline medium, the release increased to 41.75%, indicating a sustained release from the sintered 3D printed tablets. Pharmacokinetic parameters and their corresponding values of Cmax (445.38 ± 193.62 ng/mL), Tmax (02 ± 0.00 hr), AUC0-t (841.51 ± 334.13 ng.h/mL), AUC0-∞ (861.66 ± 340.54 ng.h/mL), Kel (0.61 ± 0.13 h-1), and t1/2 (1.18 ± 0.25 hr) were obtained, demonstrating effective RIF absorption in the rabbit. Additionally, an in vitro-in vivo correlation (IVIVC) model was developed, demonstrating a good correlation between in vitro release and in vivo absorption, with R2 value of 0.9696.Conclusion: The results underscore the potential of SLS 3DP technology in advancing the development of RIF-containing 3D printed tablets by sustaining in vitro dissolution following in vivo absorption profiles.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143754191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment. 工程纳米颗粒作为多形性胶质母细胞瘤治疗的一种有前途的药物递送系统。

IF 3

Therapeutic delivery Pub Date : 2025-03-25 DOI: 10.1080/20415990.2025.2484170

Seyede Nazanin Zarneshan, Faranak Aghaz

{"title":"Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment.","authors":"Seyede Nazanin Zarneshan, Faranak Aghaz","doi":"10.1080/20415990.2025.2484170","DOIUrl":"https://doi.org/10.1080/20415990.2025.2484170","url":null,"abstract":"Brain cancer has become an emerging medical disorder that poses a threat to human life due to the uncontrolled growth of cancer cells and their gradual spread to other organs. The most aggressive and life-threatening of the several types of Brain cancer is GBM. Treating GBM is difficult considering drugs are not exposed at the brain's site of action because of BBTB and BBB. Only a few cytotoxic drugs are presently used to treat GBM, including temozolomide, paclitaxel, and doxorubicin, and only temozolomide has enough BBB penetration. In this context, engineered nanoparticles are used to transport chemotherapeutic medications and reduce notable peripheral toxicity on normal cells; for necessary drug dosages. They are investigated as drug carriers to address the problem of drug resistance linked to traditional chemotherapy treatments. Many nanostructures, such as polymeric, lipid-based, and inorganic nanoparticles, have been developed as drug-delivery methods in recent decades. To be therapeutically successful as a GBM therapy, ENP formulations must diffuse through the BBB and efficiently deliver the drugs to the target cells. Various coatings and surface modifications of nanostructures can be tailored with different targeting moieties to facilitate the uptake of drug carriers by malignant cells while safeguarding healthy tissues from damage.","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-14"},"PeriodicalIF":3.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0